Cladribine suppresses disease activity in neuromyelitis optica spectrum disorder: a 2‐year follow‐up study

Neuromyelitis optica spectrum disorder (NMOSD) is a difficult condition to treat. Cladribine selectively and transiently depletes B and T lymphocytes, leading to long‐lasting immune reconstitution. This report describes observations from 24 months of follow‐up after cladribine in NMOSD patients.

[1]  H. Hartung,et al.  Targeting B Cells to Modify MS, NMOSD, and MOGAD , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[2]  F. Paul,et al.  Neuromyelitis optica , 2020, Nature Reviews Disease Primers.

[3]  A. Kermode,et al.  NMOSD acute attack: Understanding, treatment and innovative treatment prospect , 2020, Journal of Neuroimmunology.

[4]  K. Fujihara,et al.  Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[5]  F. Paul,et al.  Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica , 2020, Nature Communications.

[6]  D. Centonze,et al.  Expert opinion on the use of cladribine tablets in clinical practice , 2020, Therapeutic advances in neurological disorders.

[7]  A. Korchut,et al.  Cladribine in myasthenia gravis: a pilot open‐label study , 2019, European journal of neurology.

[8]  K. Schmierer,et al.  Potential mechanisms of action related to the efficacy and safety of cladribine. , 2019, Multiple sclerosis and related disorders.

[9]  K. Rejdak,et al.  Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study. , 2019, Multiple sclerosis and related disorders.

[10]  K. Schmierer,et al.  Cladribine: mechanisms and mysteries in multiple sclerosis , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[11]  H. Wiendl.  Cladribine — an old newcomer for pulsed immune reconstitution in MS , 2017, Nature Reviews Neurology.

[12]  H. Lassmann,et al.  Neurodegeneration in multiple sclerosis and neuromyelitis optica , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[14]  T. Kanda,et al.  Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  B. Weinshenker,et al.  Revised diagnostic criteria for neuromyelitis optica , 2006, Neurology.

[16]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.

[17]  V. Lennon,et al.  Clinical utility of testing AQP4-IgG in CSF , 2016, Neurology: Neuroimmunology & Neuroinflammation.